Peginterferon-α-2a/ribavirin
1
Reactions 1506, p22 - 21 Jun 2014 S Peginterferon-α-2a/ribavirin Guillain-Barre syndrome with acute psychosis: case report A 59-year-old woman developed Guillain-Barre syndrome with acute psychosis during treatment with peginterferon- α-2a [Pegasys] and ribavirin. The woman had received 21 weeks of therapy with peginterferon-α-2a and ribavirin for chronic hepatitis C [routes and dosages not stated]. She was hospitalised with rapidly progressive paraesthesias in her feet and arms, with weakness and numbness, along with intense pain in her low thoracic spine region. Conduction studies were modified, spine MRI was normal, and her CSF revealed albuminocytological dissociation, consistent with acute inflammatory demyelinating polyneuropathy. Peginterferon-α-2a and ribavirin were withdrawn; the woman was treated with immunoglobulin G. However, her neurological status was aggravated during the first few days of treatment, with bilateral Bell’s palsy and tetraparesis. She also developed vivid dreams and visual hallucinations, and was agitated. Her neurological symptoms improved over the following days. Her mental state abnormalities resolved after treatment with neuroleptics. After 6 weeks of neurological rehabilitation, she partially recovered. Author comment: "The first line treatment for chronic hepatitis C is the combination of PEG-IFN [peginterferon] and Ribavirin. There are a few reports of acute inflammatory demyelinating polyneuropathy (AIDP) as a neurological side effect of this therapy. Psychiatric side effects such as depressive disorders, panic attacks and mental status abnormalities are likely to appear during immunomodulating therapy but also in the course of AIDP." Vanta OM, et al. Guillain-Barre syndrome with acute psychotic disorder during therapy with PEG-IFN and Ribavirin for chronic hepatitis C: A case report. European Journal of Neurology 21 (Suppl. 1): 546 abstr. PP2246, May 2014 - Romania 803104968 1 Reactions 21 Jun 2014 No. 1506 0114-9954/14/1506-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of Peginterferon-α-2a/ribavirin
Reactions 1506, p22 - 21 Jun 2014
SPeginterferon-α-2a/ribavirin
Guillain-Barre syndrome with acute psychosis: casereport
A 59-year-old woman developed Guillain-Barre syndromewith acute psychosis during treatment with peginterferon-α-2a [Pegasys] and ribavirin.
The woman had received 21 weeks of therapy withpeginterferon-α-2a and ribavirin for chronic hepatitis C [routesand dosages not stated]. She was hospitalised with rapidlyprogressive paraesthesias in her feet and arms, with weaknessand numbness, along with intense pain in her low thoracicspine region. Conduction studies were modified, spine MRIwas normal, and her CSF revealed albuminocytologicaldissociation, consistent with acute inflammatorydemyelinating polyneuropathy.
Peginterferon-α-2a and ribavirin were withdrawn; thewoman was treated with immunoglobulin G. However, herneurological status was aggravated during the first few days oftreatment, with bilateral Bell’s palsy and tetraparesis. She alsodeveloped vivid dreams and visual hallucinations, and wasagitated. Her neurological symptoms improved over thefollowing days. Her mental state abnormalities resolved aftertreatment with neuroleptics. After 6 weeks of neurologicalrehabilitation, she partially recovered.
Author comment: "The first line treatment for chronichepatitis C is the combination of PEG-IFN [peginterferon] andRibavirin. There are a few reports of acute inflammatorydemyelinating polyneuropathy (AIDP) as a neurological sideeffect of this therapy. Psychiatric side effects such asdepressive disorders, panic attacks and mental statusabnormalities are likely to appear during immunomodulatingtherapy but also in the course of AIDP."Vanta OM, et al. Guillain-Barre syndrome with acute psychotic disorder duringtherapy with PEG-IFN and Ribavirin for chronic hepatitis C: A case report.European Journal of Neurology 21 (Suppl. 1): 546 abstr. PP2246, May 2014 -Romania 803104968
1
Reactions 21 Jun 2014 No. 15060114-9954/14/1506-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
![Ursinyova, N. , Bedford, R. B., & Gallagher, T. (2016). Copper- … · alkyl halides and (b) with key modifications including an external iodide sourcetoprovideboronicester 2a .[a]Enantiomericpurityof](https://static.fdocument.org/doc/165x107/607b466c804c7425625e49f3/ursinyova-n-bedford-r-b-gallagher-t-2016-copper-alkyl-halides.jpg)
